Basit öğe kaydını göster

PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)

dc.contributor.authorBamias, Aristotelis
dc.contributor.authorHuddart, Robert A.
dc.contributor.authorSiefker-Radtke, Arlene O.
dc.contributor.authorBalar, Arjun Vasant
dc.contributor.authorBilen, Mehmet Asim
dc.contributor.authorPowles, Thomas
dc.contributor.authorCastellano, Daniel
dc.contributor.authorKhalil, Maged F.
dc.contributor.authorVan der Heijden, Michiel Simon
dc.contributor.authorKoshkin, Vadim S.
dc.contributor.authorPook, David William
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorSantiago, Linda
dc.contributor.authorSaab, Rabih
dc.contributor.authorLi, Pao-Chen
dc.contributor.authorTagliaferri, Margit Cecile
dc.contributor.authorLin, Wei
dc.contributor.authorTagliaferri, Mary Ann
dc.contributor.authorLoriot, Yohann
dc.date.accessioned2021-03-04T17:55:16Z
dc.date.available2021-03-04T17:55:16Z
dc.identifier.citationHuddart R. A. , Siefker-Radtke A. O. , Balar A. V. , Bilen M. A. , Powles T., Bamias A., Castellano D., Khalil M. F. , Van der Heijden M. S. , Koshkin V. S. , et al., "PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)", Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38
dc.identifier.otherav_87f9a95e-d70c-4edc-a41d-0cabd9e603e6
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/92309
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.titlePIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume38
dc.contributor.firstauthorID2277804


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster